Shopping Cart 0
Cart Subtotal
USD 0

Immunosuppressants Market by Drug class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, and Others), Indication (Organ Transplantation, Autoimmune Disorders, and Non-Autoimmune Inflammatory Diseases), and Distribution channel (Hospital pharmacies, Retail pharmacies and Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global immunosuppressants market was valued at USD 13,890.0 million in 2018 and is expected to reach USD 42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants suppress the immune response or agents after organ transplantation or grafting procedures. After an organ transplantation, recipient's body produces certain immune response against it as it considers the organ as an antigen that may harm the body. These immunosuppressants help in combating hyper immune response produced by body's immune cells. These drugs are a crucial part of organ transplantation procedure as it prevents the body from serious damages.
 
Increase in incidence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidence of organ failure further propels the market growth. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of transplantation as well as immunosuppressant drugs are the limitations for the growth of this market. In addition, side effects of these drugs are expected to hamper the market growth. One of the major side effects of these drugs, especially, corticosteroids is osteoporosis. It is the condition in which density of bones is decreased, increasing the risk of fractures. Any bone in the body can be affected; however, fractures are most commonly seen in the hip, spine, or wrist. On the contrary, increase in use of tissue engineering for generation of implants provides growth opportunities for this market. In addition, rise in disposable income in developing economies, surge in awareness among individuals towards organ donation is anticipated to create lucrative opportunities in the near future.
 
The market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
 
KEY BENEFITS FOR STAKEHOLDERS
 
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Class
Corticosteroids
Monoclonal Antibodies (mAbs)
Calcineurin Inhibitors
mTOR Inhibitors
Anti-Proliferative Agents
Others
By Indication
Organ Transplantation
Autoimmune Disorders
Non-Autoimmune Inflammatory Diseases
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
 
KEY PLAYERS
 
Astellas Pharma, Inc.
Bristol Myers Squibb
AbbVie Inc.
GlaxoSmithKline Plc.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Mylan Laboratories Inc
Novartis AG
Pfizer Inc.
Sanofi S.A
 
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Forces Analysis

 

3.3.1. Moderate Bargaining Power of Buyers

3.3.2. Low Bargaining Power of Suppliers

3.3.3. Moderate Threat of Substitutes

3.3.4. Low Threat of New Entrants

3.3.5. Moderate Competitive Rivalry

 

3.4. Top Player Positioning

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. Surge In Autoimmune Disorders

3.5.1.2. Increase In Demand For Organ Transplantation

 

3.5.2. Restraint

 

3.5.2.1. Lack of Awareness Towards Organ Transplantation

 

3.5.3. Opportunity

 

3.5.3.1. Various Growth Opportunities In Emerging Economies

 

Chapter 4: Immunosuppressant Market, By Indication

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Organ Transplantation

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Share Analysis, By Country

 

4.3. Autoimmune Disorders

 

4.3.1. Key Market Trends And Growth Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Share Analysis, By Country

 

4.4. Other Diseases

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Share Analysis, By Country

 

Chapter 5: Immunosuppressant Market, By Drug Class

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Calcineurin Inhibitors

 

5.2.1. Market Size And Forecast

5.2.2. Market Share Analysis, By Country

 

5.3. Corticosteroids

 

5.3.1. Market Size And Forecast

5.3.2. Market Share Analysis, By Country

 

5.4. Monoclonal Antibodies (Mabs)

 

5.4.1. Market Size And Forecast

5.4.2. Market Share Analysis, By Country

 

5.5. Mtor Inhibitors

 

5.5.1. Market Size And Forecast

5.5.2. Market Share Analysis, By Country

 

5.6. Other Immunosuppressants

 

5.6.1. Market Size And Forecast

5.6.2. Market Share Analysis, By Country

 

Chapter 6: Immunosuppressants Market, By Distribution Channel

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Hospital Pharmacies

 

6.2.1. Market Size And Forecast

6.2.2. Market Share Analysis, By Country

 

6.3. Retail Pharmacies

 

6.3.1. Market Size And Forecast

6.3.2. Market Share Analysis, By Country

 

6.4. Online Pharmacy

 

6.4.1. Market Size And Forecast

6.4.2. Market Share Analysis, By Country

 

Chapter 7: Immunosuppressant Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends And Opportunities

7.2.2. Market Size And Forecast, By Country

7.2.3. Market Size And Forecast, By Indication

7.2.4. Market Size And Forecast, By Drug Class

7.2.5. Market Size And Forecast, By Distribution Channel

7.2.6. U.S.

 

7.2.6.1. U.S. Market Size And Forecast, By Indication

7.2.6.2. U.S. Market Size And Forecast, By Drug Class

7.2.6.3. U.S. Market Size And Forecast, By Distribution Channel

 

7.2.7. Canada

 

7.2.7.1. Canada Market Size And Forecast, By Indication

7.2.7.2. Canada Market Size And Forecast, By Drug Class

7.2.7.3. Canada Market Size And Forecast, By Distribution Channel

 

7.2.8. Mexico

 

7.2.8.1. Mexico Market Size And Forecast, By Indication

7.2.8.2. Mexico Market Size And Forecast, By Drug Class

7.2.8.3. Mexico Market Size And Forecast, By Distribution Channel

 

7.3. Europe

 

7.3.1. Key Growth Factors And Opportunities

7.3.2. Market Size And Forecast, By Country

7.3.3. Market Size And Forecast, By Indication

7.3.4. Market Size And Forecast, By Drug Class

7.3.5. Market Size And Forecast, By Distribution Channel

7.3.6. Germany

 

7.3.6.1. Germany Market Size And Forecast, By Indication

7.3.6.2. Germany Market Size And Forecast, By Drug Class

7.3.6.3. Germany Market Size And Forecast, By Distribution Channel

 

7.3.7. France

 

7.3.7.1. France Market Size And Forecast, By Indication

7.3.7.2. France Market Size And Forecast, By Drug Class

7.3.7.3. France Market Size And Forecast, By Distribution Channel

 

7.3.8. Uk

 

7.3.8.1. Uk Market Size And Forecast, By Indication

7.3.8.2. Uk Market Size And Forecast, By Drug Class

7.3.8.3. Uk Market Size And Forecast, By Distribution Channel

 

7.3.9. Italy

 

7.3.9.1. Italy Market Size And Forecast, By Indication

7.3.9.2. Italy Market Size And Forecast, By Drug Class

7.3.9.3. Italy Market Size And Forecast, By Distribution Channel

 

7.3.10. Rest of Europe

 

7.3.10.1. Rest of Europe Market Size And Forecast, By Indication

7.3.10.2. Rest of Europe Market Size And Forecast, By Drug Class

7.3.10.3. Rest of Europe Market Size And Forecast, By Distribution Channel

 

7.4. Asia-Pacific

 

7.4.1. Key Growth Factors And Opportunities.

7.4.2. Market Size And Forecast, By Country

7.4.3. Market Size And Forecast, By Indication

7.4.4. Market Size And Forecast, By Drug Class

7.4.5. Market Size And Forecast, By Distribution Channel

7.4.6. Japan

 

7.4.6.1. Japan Market Size And Forecast, By Indication

7.4.6.2. Japan Market Size And Forecast, By Drug Class

7.4.6.3. Japan Market Size And Forecast, By Distribution Channel

 

7.4.7. China

 

7.4.7.1. China Market Size And Forecast, By Indication

7.4.7.2. China Market Size And Forecast, By Drug Class

7.4.7.3. China Market Size And Forecast, By Distribution Channel

 

7.4.8. India

 

7.4.8.1. India Market Size And Forecast, By Indication

7.4.8.2. India Market Size And Forecast, By Drug Class

7.4.8.3. India Market Size And Forecast, By Distribution Channel

 

7.4.9. Australia

 

7.4.9.1. Australia Market Size And Forecast By Indication

7.4.9.2. Australia Market Size And Forecast, By Drug Class

7.4.9.3. Australia Market Size And Forecast, By Distribution Channel

 

7.4.10. Rest of Asia-Pacific

 

7.4.10.1. Rest of Asia-Pacific Market Size And Forecast By Indication

7.4.10.2. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

7.4.10.3. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

 

7.5. Lamea

 

7.5.1. Key Growth Factors And Opportunities

7.5.2. Market Size And Forecast, By Country

7.5.3. Market Size And Forecast, By Indication

7.5.4. Market Size And Forecast, By Drug Class

7.5.5. Market Size And Forecast, By Distribution Channel

7.5.6. Brazil

 

7.5.6.1. Brazil Market Size And Forecast, By Indication

7.5.6.2. Brazil Market Size And Forecast, By Drug Class

7.5.6.3. Brazil Market Size And Forecast, By Distribution Channel

 

7.5.7. Saudi Arabia

 

7.5.7.1. Saudi Arabia Market Size And Forecast, By Indication

7.5.7.2. Saudi Arabia Market Size And Forecast, By Drug Class

7.5.7.3. Saudi Arabia Market Size And Forecast, By Distribution Channel

 

7.5.8. South Africa

 

7.5.8.1. South Africa Market Size And Forecast, By Indication

7.5.8.2. South Africa Market Size And Forecast, By Drug Class

7.5.8.3. South Africa Market Size And Forecast, By Distribution Channel

 

7.5.9. Rest of Lamea

 

7.5.9.1. Rest of Lamea Market Size And Forecast, By Indication

7.5.9.2. Rest of Lamea Market Size And Forecast, By Drug Class

7.5.9.3. Rest of Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Astellas Pharma Inc.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

 

8.3. Bristol-Myers Squibb Company

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

8.3.6. Key Strategic Moves And Developments

 

8.4. Glaxosmithkline Plc.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Business Performance

8.4.6. Key Strategic Moves And Developments

 

8.5. Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.)

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

 

8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

8.6.6. Key Strategic Moves And Developments

 

8.7. Mylan N.V.

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

8.7.6. Key Strategic Moves And Developments

 

8.8. Novartis International Ag (Sandoz)

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

8.8.6. Key Strategic Moves And Developments

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

8.9.6. Key Strategic Moves And Developments

 

8.10. Sanofi S.A.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance

8.10.6. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Immunosuppressant, Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Top Player Positioning

Figure 04. Drivers, Restraint, And Opportunity, Immunosuppressants Market

Figure 05. Comparative Share Analysis of Immunosuppresants Market For Organ Transplantation, By Country, 2018 & 2026 (%)

Figure 06. Comparative Share Analysis of Immunosuppressant Market For Autoimmune Disorders Market, By Country, 2018 & 2026 (%)

Figure 07. Comparative Share Analysis of Immunosuppressants Market For Others, By Country, 2018 & 2026 (%)

Figure 08. Comparative Share Analysis of Calcineurin Inhibitors Market, By Country, 2018 & 2026 (%)

Figure 09. Comparative Share Analysis of Corticosteroidss Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 10. Comparative Share Analysis of Monoclonal Antibodies Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Mtor Inhibitors Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Other Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Immunosuppressant Market For Hospital Pharmacies, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Retail Pharmacies Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Online Pharmecy Market, By Country, 2018 & 2026 (%)

Figure 16. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 17. Abbvie: Revenue Share By Segment, 2018 (%)

Figure 18. Abbvie: Revenue Share By Region, 2018 (%)

Figure 19. Astellas: Sales, 2016-2018 (USD Million)

Figure 20. Astellas: Sales Share By Products And Services, 2018 (%)

Figure 21. Astellas: Revenue Share By Region, 2018 (%)

Figure 22. Bms: Net Sales, 2016-2018 (USD Million)

Figure 23. Bms: Revenue Share By Region, 2018 (%)

Figure 24. Gsk: Revenue, 2016-2018 (USD Million)

Figure 25. Gsk: Revenue Share By Segment, 2018 (%)

Figure 26. Gsk: Revenue Share By Region, 2018 (%)

Figure 27. Intas: Revenue, 2016-2018 (USD Million)

Figure 28. Intas: Revenue Share By Region, 2018 (%)

Figure 29. J&J: Revenue, 2016-2018 (USD Million)

Figure 30. J&J: Revenue Share By Segment, 2018 (%)

Figure 31. J&J: Revenue Share By Region, 2018 (%)

Figure 32. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 33. Mylan: Revenue Share By Geography, 2018 (%)

Figure 34. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 35. Novartis: Revenue Share By Segment, 2018 (%)

Figure 36. Novartis: Revenue Share By Geography, 2018 (%)

Figure 37. Pfizer: Revenue, 2016-2018 (USD Million)

Figure 38. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 39. Pfizer: Revenue Share By Region, 2018 (%)

Figure 40. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 41. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 42. Sanofi: Revenue Share By Region, 2018 (%)

 


List Of Table

List of Tables

 

Table 01. Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 02. Immunosuppresants Market For Organ Transplantation Market, By Region, 2018-2026 (USD Million)

Table 03. Immunosuppressant Market For Autoimmune Disorders, By Region, 2018-2026 (USD Million)

Table 04. Immunosuppressants Market For Others, By Region, 2018-2026 (USD Million)

Table 05. Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 06. Calcineurin Inhibitors Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 07. Immunosuppressant Corticosteroidss Market, By Region, 2018-2026 (USD Million)

Table 08. Monoclonal Antibodies Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 09. Mtor Inhibitors Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 10. Other Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 11. Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 12. Immunosuppressant Market For Hospital Pharmacies, By Region, 2018-2026 (USD Million)

Table 13. Immunosuppressant Corticosteroidss Market For Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 14. Immunosuppressant Market For Online Pharmacy, By Region, 2018-2026 (USD Million)

Table 15. Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 16. North America Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 17. North America Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 18. North America Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 19. North America Immunosuppressant Market, By Distribution Cahnnel, 2018-2026 (USD Million)

Table 20. U.S. Immunosuppressant Market By Indication, 2018-2026 (USD Million)

Table 21. U.S. Immunosuppressant Market By Drug Class, 2018-2026 (USD Million)

Table 22. U.S. Immunosuppressant Market By Distribution Channel, 2018-2026 (USD Million)

Table 23. Canada Immunosuppressant Market By Indication, 2018-2026 (USD Million)

Table 24. Canada Immunosuppressant Market By Drug Class, 2018-2026 (USD Million)

Table 25. Canada Immunosuppressant Market By Distribution Channel, 2018-2026 (USD Million)

Table 26. Mexico Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 27. Mexico Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 28. Mexico Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 29. Europe Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 30. Europe Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 31. Europe Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 32. Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 33. Germany Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 34. Germany Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 35. Germany Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 36. France Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 37. France Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 38. France Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 39. U.K. Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 40. U.K. Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 41. U.K. Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 42. Italy Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 43. Italy Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 44. Italy Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 45. Rest of Europe Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 46. Rest of Europe Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 47. Rest of Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 48. Asia-Pacific Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 49. Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 50. Asia-Pacific Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 51. Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 52. Japan Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 53. Japan Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 54. Japan Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 55. China Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 56. China Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 57. China Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 58. India Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 59. India Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 60. India Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 61. Australia Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 62. Australia Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 63. Australia Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 64. Rest of Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 65. Rest of Asia-Pacific Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 66. Rest of Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 67. Lamea Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 68. Lamea Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 69. Lamea Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 70. Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 71. Brazil Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 72. Brazil Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 73. Brazil Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 74. Saudi Arabia Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 75. Saudi Arabia Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 76. Saudi Arabia Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 77. South Africa Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 78. South Africa Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 79. South Africa Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 80. Rest of Lamea Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 81. Rest of Lamea Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 82. Rest of Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 83. Abbvie: Company Snapshot

Table 84. Abbvie: Operating Segments

Table 85. Abbott: Product Portfolio

Table 86. Astellas: Company Snapshot

Table 87. Astellas: Products And Services

Table 88. Astellas: Product Portfolio

Table 89. Bms: Company Snapshot

Table 90. Bms: Product Portfolio

Table 91. Gsk: Company Snapshot

Table 92. Gsk: Operating Segments

Table 93. Gsk: Product Portfolio

Table 94. Intas: Company Snapshot

Table 95. Intas: Product Portfolio

Table 96. J&J: Company Snapshot

Table 97. J&J: Operating Segments

Table 98. J&J: Product Portfolio

Table 99. Mylan: Company Snapshot

Table 100. Mylan: Operating Segments

Table 101. Mylan: Product Portfolio

Table 102. Novartis Ag: Company Snapshot

Table 103. Novartis: Operating Segments

Table 104. Novartis Ag: Product Portfolio

Table 105. Pfizer: Company Snapshot

Table 106. Pfizer: Operating Segments

Table 107. Pfizer: Product Portfolio

Table 108. Sanofi: Company Snapshot

Table 109. Sanofi: Operating Segments

Table 110. Sanofi: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., Sanofi S.A.

Company Profile

Company Profile Title

The global immunosuppressants market was valued at USD 13,890.0 million in 2018 and is expected to reach USD 42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants suppress the immune response or agents after organ transplantation or grafting procedures. After an organ transplantation, recipient's body produces certain immune response against it as it considers the organ as an antigen that may harm the body. These immunosuppressants help in combating hyper immune response produced by body's immune cells. These drugs are a crucial part of organ transplantation procedure as it prevents the body from serious damages.
 
Increase in incidence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidence of organ failure further propels the market growth. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of transplantation as well as immunosuppressant drugs are the limitations for the growth of this market. In addition, side effects of these drugs are expected to hamper the market growth. One of the major side effects of these drugs, especially, corticosteroids is osteoporosis. It is the condition in which density of bones is decreased, increasing the risk of fractures. Any bone in the body can be affected; however, fractures are most commonly seen in the hip, spine, or wrist. On the contrary, increase in use of tissue engineering for generation of implants provides growth opportunities for this market. In addition, rise in disposable income in developing economies, surge in awareness among individuals towards organ donation is anticipated to create lucrative opportunities in the near future.
 
The market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
 
KEY BENEFITS FOR STAKEHOLDERS
 
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Class
Corticosteroids
Monoclonal Antibodies (mAbs)
Calcineurin Inhibitors
mTOR Inhibitors
Anti-Proliferative Agents
Others
By Indication
Organ Transplantation
Autoimmune Disorders
Non-Autoimmune Inflammatory Diseases
By Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
 
KEY PLAYERS
 
Astellas Pharma, Inc.
Bristol Myers Squibb
AbbVie Inc.
GlaxoSmithKline Plc.
Intas Pharmaceuticals Ltd.
Johnson & Johnson
Mylan Laboratories Inc
Novartis AG
Pfizer Inc.
Sanofi S.A
 
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

 

3.3. Porter'S Five Forces Analysis

 

3.3.1. Moderate Bargaining Power of Buyers

3.3.2. Low Bargaining Power of Suppliers

3.3.3. Moderate Threat of Substitutes

3.3.4. Low Threat of New Entrants

3.3.5. Moderate Competitive Rivalry

 

3.4. Top Player Positioning

3.5. Market Dynamics

 

3.5.1. Drivers

 

3.5.1.1. Surge In Autoimmune Disorders

3.5.1.2. Increase In Demand For Organ Transplantation

 

3.5.2. Restraint

 

3.5.2.1. Lack of Awareness Towards Organ Transplantation

 

3.5.3. Opportunity

 

3.5.3.1. Various Growth Opportunities In Emerging Economies

 

Chapter 4: Immunosuppressant Market, By Indication

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Organ Transplantation

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast

4.2.3. Market Share Analysis, By Country

 

4.3. Autoimmune Disorders

 

4.3.1. Key Market Trends And Growth Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Share Analysis, By Country

 

4.4. Other Diseases

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Share Analysis, By Country

 

Chapter 5: Immunosuppressant Market, By Drug Class

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Calcineurin Inhibitors

 

5.2.1. Market Size And Forecast

5.2.2. Market Share Analysis, By Country

 

5.3. Corticosteroids

 

5.3.1. Market Size And Forecast

5.3.2. Market Share Analysis, By Country

 

5.4. Monoclonal Antibodies (Mabs)

 

5.4.1. Market Size And Forecast

5.4.2. Market Share Analysis, By Country

 

5.5. Mtor Inhibitors

 

5.5.1. Market Size And Forecast

5.5.2. Market Share Analysis, By Country

 

5.6. Other Immunosuppressants

 

5.6.1. Market Size And Forecast

5.6.2. Market Share Analysis, By Country

 

Chapter 6: Immunosuppressants Market, By Distribution Channel

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. Hospital Pharmacies

 

6.2.1. Market Size And Forecast

6.2.2. Market Share Analysis, By Country

 

6.3. Retail Pharmacies

 

6.3.1. Market Size And Forecast

6.3.2. Market Share Analysis, By Country

 

6.4. Online Pharmacy

 

6.4.1. Market Size And Forecast

6.4.2. Market Share Analysis, By Country

 

Chapter 7: Immunosuppressant Market, By Region

 

7.1. Overview

 

7.1.1. Market Size And Forecast

 

7.2. North America

 

7.2.1. Key Market Trends And Opportunities

7.2.2. Market Size And Forecast, By Country

7.2.3. Market Size And Forecast, By Indication

7.2.4. Market Size And Forecast, By Drug Class

7.2.5. Market Size And Forecast, By Distribution Channel

7.2.6. U.S.

 

7.2.6.1. U.S. Market Size And Forecast, By Indication

7.2.6.2. U.S. Market Size And Forecast, By Drug Class

7.2.6.3. U.S. Market Size And Forecast, By Distribution Channel

 

7.2.7. Canada

 

7.2.7.1. Canada Market Size And Forecast, By Indication

7.2.7.2. Canada Market Size And Forecast, By Drug Class

7.2.7.3. Canada Market Size And Forecast, By Distribution Channel

 

7.2.8. Mexico

 

7.2.8.1. Mexico Market Size And Forecast, By Indication

7.2.8.2. Mexico Market Size And Forecast, By Drug Class

7.2.8.3. Mexico Market Size And Forecast, By Distribution Channel

 

7.3. Europe

 

7.3.1. Key Growth Factors And Opportunities

7.3.2. Market Size And Forecast, By Country

7.3.3. Market Size And Forecast, By Indication

7.3.4. Market Size And Forecast, By Drug Class

7.3.5. Market Size And Forecast, By Distribution Channel

7.3.6. Germany

 

7.3.6.1. Germany Market Size And Forecast, By Indication

7.3.6.2. Germany Market Size And Forecast, By Drug Class

7.3.6.3. Germany Market Size And Forecast, By Distribution Channel

 

7.3.7. France

 

7.3.7.1. France Market Size And Forecast, By Indication

7.3.7.2. France Market Size And Forecast, By Drug Class

7.3.7.3. France Market Size And Forecast, By Distribution Channel

 

7.3.8. Uk

 

7.3.8.1. Uk Market Size And Forecast, By Indication

7.3.8.2. Uk Market Size And Forecast, By Drug Class

7.3.8.3. Uk Market Size And Forecast, By Distribution Channel

 

7.3.9. Italy

 

7.3.9.1. Italy Market Size And Forecast, By Indication

7.3.9.2. Italy Market Size And Forecast, By Drug Class

7.3.9.3. Italy Market Size And Forecast, By Distribution Channel

 

7.3.10. Rest of Europe

 

7.3.10.1. Rest of Europe Market Size And Forecast, By Indication

7.3.10.2. Rest of Europe Market Size And Forecast, By Drug Class

7.3.10.3. Rest of Europe Market Size And Forecast, By Distribution Channel

 

7.4. Asia-Pacific

 

7.4.1. Key Growth Factors And Opportunities.

7.4.2. Market Size And Forecast, By Country

7.4.3. Market Size And Forecast, By Indication

7.4.4. Market Size And Forecast, By Drug Class

7.4.5. Market Size And Forecast, By Distribution Channel

7.4.6. Japan

 

7.4.6.1. Japan Market Size And Forecast, By Indication

7.4.6.2. Japan Market Size And Forecast, By Drug Class

7.4.6.3. Japan Market Size And Forecast, By Distribution Channel

 

7.4.7. China

 

7.4.7.1. China Market Size And Forecast, By Indication

7.4.7.2. China Market Size And Forecast, By Drug Class

7.4.7.3. China Market Size And Forecast, By Distribution Channel

 

7.4.8. India

 

7.4.8.1. India Market Size And Forecast, By Indication

7.4.8.2. India Market Size And Forecast, By Drug Class

7.4.8.3. India Market Size And Forecast, By Distribution Channel

 

7.4.9. Australia

 

7.4.9.1. Australia Market Size And Forecast By Indication

7.4.9.2. Australia Market Size And Forecast, By Drug Class

7.4.9.3. Australia Market Size And Forecast, By Distribution Channel

 

7.4.10. Rest of Asia-Pacific

 

7.4.10.1. Rest of Asia-Pacific Market Size And Forecast By Indication

7.4.10.2. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

7.4.10.3. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel

 

7.5. Lamea

 

7.5.1. Key Growth Factors And Opportunities

7.5.2. Market Size And Forecast, By Country

7.5.3. Market Size And Forecast, By Indication

7.5.4. Market Size And Forecast, By Drug Class

7.5.5. Market Size And Forecast, By Distribution Channel

7.5.6. Brazil

 

7.5.6.1. Brazil Market Size And Forecast, By Indication

7.5.6.2. Brazil Market Size And Forecast, By Drug Class

7.5.6.3. Brazil Market Size And Forecast, By Distribution Channel

 

7.5.7. Saudi Arabia

 

7.5.7.1. Saudi Arabia Market Size And Forecast, By Indication

7.5.7.2. Saudi Arabia Market Size And Forecast, By Drug Class

7.5.7.3. Saudi Arabia Market Size And Forecast, By Distribution Channel

 

7.5.8. South Africa

 

7.5.8.1. South Africa Market Size And Forecast, By Indication

7.5.8.2. South Africa Market Size And Forecast, By Drug Class

7.5.8.3. South Africa Market Size And Forecast, By Distribution Channel

 

7.5.9. Rest of Lamea

 

7.5.9.1. Rest of Lamea Market Size And Forecast, By Indication

7.5.9.2. Rest of Lamea Market Size And Forecast, By Drug Class

7.5.9.3. Rest of Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 8: Company Profiles

 

8.1. Abbvie Inc.

 

8.1.1. Company Overview

8.1.2. Company Snapshot

8.1.3. Operating Business Segments

8.1.4. Product Portfolio

8.1.5. Business Performance

8.1.6. Key Strategic Moves And Developments

 

8.2. Astellas Pharma Inc.

 

8.2.1. Company Overview

8.2.2. Company Snapshot

8.2.3. Operating Business Segments

8.2.4. Product Portfolio

8.2.5. Business Performance

 

8.3. Bristol-Myers Squibb Company

 

8.3.1. Company Overview

8.3.2. Company Snapshot

8.3.3. Operating Business Segments

8.3.4. Product Portfolio

8.3.5. Business Performance

8.3.6. Key Strategic Moves And Developments

 

8.4. Glaxosmithkline Plc.

 

8.4.1. Company Overview

8.4.2. Company Snapshot

8.4.3. Operating Business Segments

8.4.4. Product Portfolio

8.4.5. Business Performance

8.4.6. Key Strategic Moves And Developments

 

8.5. Intas Pharmaceuticals Ltd. (Accord Healthcare Ltd.)

 

8.5.1. Company Overview

8.5.2. Company Snapshot

8.5.3. Operating Business Segments

8.5.4. Product Portfolio

8.5.5. Business Performance

 

8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

 

8.6.1. Company Overview

8.6.2. Company Snapshot

8.6.3. Operating Business Segments

8.6.4. Product Portfolio

8.6.5. Business Performance

8.6.6. Key Strategic Moves And Developments

 

8.7. Mylan N.V.

 

8.7.1. Company Overview

8.7.2. Company Snapshot

8.7.3. Operating Business Segments

8.7.4. Product Portfolio

8.7.5. Business Performance

8.7.6. Key Strategic Moves And Developments

 

8.8. Novartis International Ag (Sandoz)

 

8.8.1. Company Overview

8.8.2. Company Snapshot

8.8.3. Operating Business Segments

8.8.4. Product Portfolio

8.8.5. Business Performance

8.8.6. Key Strategic Moves And Developments

 

8.9. Pfizer Inc.

 

8.9.1. Company Overview

8.9.2. Company Snapshot

8.9.3. Operating Business Segments

8.9.4. Product Portfolio

8.9.5. Business Performance

8.9.6. Key Strategic Moves And Developments

 

8.10. Sanofi S.A.

 

8.10.1. Company Overview

8.10.2. Company Snapshot

8.10.3. Operating Business Segments

8.10.4. Product Portfolio

8.10.5. Business Performance

8.10.6. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Immunosuppressant, Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Top Player Positioning

Figure 04. Drivers, Restraint, And Opportunity, Immunosuppressants Market

Figure 05. Comparative Share Analysis of Immunosuppresants Market For Organ Transplantation, By Country, 2018 & 2026 (%)

Figure 06. Comparative Share Analysis of Immunosuppressant Market For Autoimmune Disorders Market, By Country, 2018 & 2026 (%)

Figure 07. Comparative Share Analysis of Immunosuppressants Market For Others, By Country, 2018 & 2026 (%)

Figure 08. Comparative Share Analysis of Calcineurin Inhibitors Market, By Country, 2018 & 2026 (%)

Figure 09. Comparative Share Analysis of Corticosteroidss Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 10. Comparative Share Analysis of Monoclonal Antibodies Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Mtor Inhibitors Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Other Immunosuppressant Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Immunosuppressant Market For Hospital Pharmacies, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Retail Pharmacies Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Online Pharmecy Market, By Country, 2018 & 2026 (%)

Figure 16. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 17. Abbvie: Revenue Share By Segment, 2018 (%)

Figure 18. Abbvie: Revenue Share By Region, 2018 (%)

Figure 19. Astellas: Sales, 2016-2018 (USD Million)

Figure 20. Astellas: Sales Share By Products And Services, 2018 (%)

Figure 21. Astellas: Revenue Share By Region, 2018 (%)

Figure 22. Bms: Net Sales, 2016-2018 (USD Million)

Figure 23. Bms: Revenue Share By Region, 2018 (%)

Figure 24. Gsk: Revenue, 2016-2018 (USD Million)

Figure 25. Gsk: Revenue Share By Segment, 2018 (%)

Figure 26. Gsk: Revenue Share By Region, 2018 (%)

Figure 27. Intas: Revenue, 2016-2018 (USD Million)

Figure 28. Intas: Revenue Share By Region, 2018 (%)

Figure 29. J&J: Revenue, 2016-2018 (USD Million)

Figure 30. J&J: Revenue Share By Segment, 2018 (%)

Figure 31. J&J: Revenue Share By Region, 2018 (%)

Figure 32. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 33. Mylan: Revenue Share By Geography, 2018 (%)

Figure 34. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 35. Novartis: Revenue Share By Segment, 2018 (%)

Figure 36. Novartis: Revenue Share By Geography, 2018 (%)

Figure 37. Pfizer: Revenue, 2016-2018 (USD Million)

Figure 38. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 39. Pfizer: Revenue Share By Region, 2018 (%)

Figure 40. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 41. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 42. Sanofi: Revenue Share By Region, 2018 (%)

 


List Of Table

List of Tables

 

Table 01. Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 02. Immunosuppresants Market For Organ Transplantation Market, By Region, 2018-2026 (USD Million)

Table 03. Immunosuppressant Market For Autoimmune Disorders, By Region, 2018-2026 (USD Million)

Table 04. Immunosuppressants Market For Others, By Region, 2018-2026 (USD Million)

Table 05. Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 06. Calcineurin Inhibitors Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 07. Immunosuppressant Corticosteroidss Market, By Region, 2018-2026 (USD Million)

Table 08. Monoclonal Antibodies Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 09. Mtor Inhibitors Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 10. Other Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 11. Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 12. Immunosuppressant Market For Hospital Pharmacies, By Region, 2018-2026 (USD Million)

Table 13. Immunosuppressant Corticosteroidss Market For Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 14. Immunosuppressant Market For Online Pharmacy, By Region, 2018-2026 (USD Million)

Table 15. Immunosuppressant Market, By Region, 2018-2026 (USD Million)

Table 16. North America Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 17. North America Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 18. North America Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 19. North America Immunosuppressant Market, By Distribution Cahnnel, 2018-2026 (USD Million)

Table 20. U.S. Immunosuppressant Market By Indication, 2018-2026 (USD Million)

Table 21. U.S. Immunosuppressant Market By Drug Class, 2018-2026 (USD Million)

Table 22. U.S. Immunosuppressant Market By Distribution Channel, 2018-2026 (USD Million)

Table 23. Canada Immunosuppressant Market By Indication, 2018-2026 (USD Million)

Table 24. Canada Immunosuppressant Market By Drug Class, 2018-2026 (USD Million)

Table 25. Canada Immunosuppressant Market By Distribution Channel, 2018-2026 (USD Million)

Table 26. Mexico Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 27. Mexico Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 28. Mexico Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 29. Europe Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 30. Europe Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 31. Europe Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 32. Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 33. Germany Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 34. Germany Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 35. Germany Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 36. France Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 37. France Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 38. France Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 39. U.K. Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 40. U.K. Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 41. U.K. Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 42. Italy Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 43. Italy Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 44. Italy Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 45. Rest of Europe Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 46. Rest of Europe Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 47. Rest of Europe Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 48. Asia-Pacific Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 49. Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 50. Asia-Pacific Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 51. Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 52. Japan Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 53. Japan Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 54. Japan Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 55. China Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 56. China Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 57. China Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 58. India Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 59. India Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 60. India Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 61. Australia Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 62. Australia Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 63. Australia Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 64. Rest of Asia-Pacific Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 65. Rest of Asia-Pacific Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 66. Rest of Asia-Pacific Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 67. Lamea Immunosuppressant Market, By Country, 2018-2026 (USD Million)

Table 68. Lamea Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 69. Lamea Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million),

Table 70. Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 71. Brazil Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 72. Brazil Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 73. Brazil Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 74. Saudi Arabia Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 75. Saudi Arabia Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 76. Saudi Arabia Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 77. South Africa Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 78. South Africa Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 79. South Africa Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 80. Rest of Lamea Immunosuppressant Market, By Indication, 2018-2026 (USD Million)

Table 81. Rest of Lamea Immunosuppressant Market, By Drug Class, 2018-2026 (USD Million)

Table 82. Rest of Lamea Immunosuppressant Market, By Distribution Channel, 2018-2026 (USD Million)

Table 83. Abbvie: Company Snapshot

Table 84. Abbvie: Operating Segments

Table 85. Abbott: Product Portfolio

Table 86. Astellas: Company Snapshot

Table 87. Astellas: Products And Services

Table 88. Astellas: Product Portfolio

Table 89. Bms: Company Snapshot

Table 90. Bms: Product Portfolio

Table 91. Gsk: Company Snapshot

Table 92. Gsk: Operating Segments

Table 93. Gsk: Product Portfolio

Table 94. Intas: Company Snapshot

Table 95. Intas: Product Portfolio

Table 96. J&J: Company Snapshot

Table 97. J&J: Operating Segments

Table 98. J&J: Product Portfolio

Table 99. Mylan: Company Snapshot

Table 100. Mylan: Operating Segments

Table 101. Mylan: Product Portfolio

Table 102. Novartis Ag: Company Snapshot

Table 103. Novartis: Operating Segments

Table 104. Novartis Ag: Product Portfolio

Table 105. Pfizer: Company Snapshot

Table 106. Pfizer: Operating Segments

Table 107. Pfizer: Product Portfolio

Table 108. Sanofi: Company Snapshot

Table 109. Sanofi: Operating Segments

Table 110. Sanofi: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., Sanofi S.A.